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A B S T R A C T
The fluroquinolone gemifloxacin was examined for its capacity to modulate secretion of cytokines by
human monocytes stimulated with lipopolysaccharide (LPS). Monocytes from six male and two female
healthy volunteers were stimulated with LPS, exposed to gemifloxacin and the amounts of secreted IL-
1a, IL-1b, IL-6, IL-10 and TNF-a measured at 3, 6 and 24 h. The results revealed that LPS alone increased
secretion of each cytokine significantly. Treatment of the LPS-stimulated monocytes with gemifloxacin
resulted in a significant inhibition (p < 0.01) of secretion of each of the cytokines from monocytes of the
eight volunteers. Nuclear extracts of the human monocyte cell line, THP-1, were used in the
electrophoretic mobility shift assay to determine whether gemifloxacin affects nuclear factor-jB (NF-jB)
activation. In addition, RNA from THP-1 cells was used in Northern blots to determine whether
inhibition of secretion of IL-1b and TNF-a by gemifloxacin occurred at the transcription or translation
level. Whereas LPS induced a rapid increase in NF-jB activation, gemifloxacin alone did not.
Gemifloxacin did not affect the kinetics or decrease the extent of activation. Northern blots indicated that
the inhibitory activity of gemifloxacin occurred post-transcription. Thus, gemifloxacin may modulate the
immune response by altering secretion of cytokines by human monocytes. Although the concentrations
of gemifloxacin used were higher than those observed in the serum of human volunteers treated with
the dose under clinical development, it should be taken into consideration that concentrations at tissue
and intracellular levels may be considerably higher than serum concentrations.
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I N T R O D U C T I O N
A number of antibiotics have been found to have
significant immunomodulatory properties both
in vitro and in animal models in vivo [1,2]. Such
properties may have clinical significance for
modulation of the immune response of patients
[3–5]. Previous work has shown that the fluoro-
quinolones trovafloxacin and moxifloxacin inhibit
secretion of cytokines significantly, particularly
IL-1a and TNF-a, by human monocytes stimula-
ted in vitro with lipopolysaccharide (LPS) [6,7]. In
addition, treatment with clindamycin [2], trovafl-
oxacin and the fluoroquinolones, ciprofloxacin
and tosufloxacin [1] protected mice from early
death following intravenous injection of a lethal
dose of LPS. Thus, fluoroquinolones may play a
dual role in infections by having an antimicrobial
effect and an effect on either the beneficial or the
detrimental host response per se [4,8,9].
An interest in the role of cytokines in the
immunopathogenesis of infection [10], together
with previous work demonstrating the capacity of
certain antibiotics to modulate the production of
cytokines by human monocytes [6,7,11,12],
prompted an examination of the effects of gemi-
floxacin on the in-vitro production of cytokines by
human monocytes stimulated with LPS. Gemi-
floxacin is a highly active fluoroquinolone which
exhibits broad-spectrum activity, with particular
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potency against penicillin-susceptible and -resist-
ant strains of Streptococcus pneumoniae [13]. The
MIC90 for 602 isolates of S. pneumoniae was
0.06 mg ⁄L, compared to 0.25 mg ⁄L for trovafl-
oxacin, 0.12 mg ⁄L for grepafloxacin, and 1 mg ⁄L
for levofloxacin [14]. The MIC90 range of gemifl-
oxacin for 80 isolates of Escherichia coli was 0.002–
128 mg ⁄L, compared to 0.002–128 mg ⁄L for ci-
profloxacin, 0.015–64 mg ⁄L for levofloxacin, and
0.004–128 mg ⁄L for trovafloxacin [15]. When the
results revealed that gemifloxacin strongly inhib-
ited secretion of cytokines, the cellular level of this
inhibitory activity was examined by determining
the effect of gemifloxacin on activation of the
transcription factor NF-jB and regulation of
levels of cytokine mRNA.
M A T E R I A L S A N D M E T H O D S
Reagents
Gemifloxacin was obtained from SmithKline Beecham (Col-
legeville, PA, USA). Stock solutions and further dilutions were
made in RPMI 1640 medium (Gibco BRL, Grand Island, NY,
USA). LPS (from Escherichia coli O26:B6) was purchased from
Difco (Detroit, MI, USA).
Isolation of monocyte-enriched peripheral blood
mononuclear cells
Blood was obtained from six male and two female healthy
volunteers (aged 20–57 years). Written authorised consent was
obtained from each volunteer. Mononuclear cells (PBMC) were
cultured as described previously [6,7]. Briefly, cells were
separated on Ficoll-Paque (Pharmacia Biotech, Uppsala, Swe-
den) density gradients, washed twice with calcium and
magnesium-free phosphate-buffered saline (PBS; Mediatech,
Herndon, VA, USA), and fractionated by centrifugation over
discontinuous Percoll (Pharmacia Biotech) gradients. The
monocyte-enriched cell fraction was collected and washed
with PBS free of calcium and magnesium. Thereafter, the cells
were resuspended in RPMI 1640 (with 25 mM HEPES,
L-glutamine; Mediatech) containing fetal bovine serum (FBS)
10% v ⁄v (Gibco BRL) at a density of 1 · 106 cells ⁄mL.
Characterisation of the monocytes was done with the Naph-
thol AS-D Chloroacetate Esterase and a-Naphthyl Acetate
Esterase kit (Sigma, St. Louis, MO, USA). At least 90% of the
cells were identified as monocytes.
In-vitro cytokine assays
Purified monocytes were seeded into 24-well plates (Costar
Corporation, Cambridge, MA, USA), at a density of 1 · 106
cells ⁄mL (1 mL ⁄well), and incubated in the presence of either
LPS alone 0.00001 mg ⁄L, or LPS plus gemifloxacin 0.001 mg ⁄L,
0.005 mg ⁄L, or 0.010 mg ⁄L for 3, 6, or 24 h at 37 C in a CO2 5%
v ⁄v incubator. At each period, cell-free supernatants were
recovered by centrifugation and stored at ) 20 C until assayed
for cytokines. The concentration of interleukin-1a (IL-1a) IL-1b,
IL-6, IL-10, and TNF-a was determined by enzyme-linked
immunosorbent assay (ELISA) using commercially available
reagents (PharMingen, San Diego, CA, USA). Quantification
was performed by means of a standard curve derived by linear
dilution of the cytokine standards included in the respective
reagent kit. The detection limit for IL-1a and IL-10 was
8 pg ⁄mL, for IL-6 and TNF-a was 20 pg ⁄mL, and for IL-1b
was 3.9 pg ⁄mL. In reproducibility assays for each cytokine, the
coefficient of variation (%CV) was < 12% in replicate assays
from the same sample. Cytokine assays were performed in
quadruplicate, using the supernatant samples or appropriate
dilutions of the supernatants, as determined in preliminary
studies.
Cellular toxicity assay
Toxicity of gemifloxacin for the purified monocytes was
determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide cytotoxicity assay with a Cell Titer 96 Kit
(MTT assay; Promega, Madison, WI, USA). Briefly, cells were
plated in quadruplicate wells at 1 · 103 cells ⁄well. Following
incubation for 4 h at 37 C in a CO2 5% v ⁄v incubator,
gemifloxacin concentrations of 0.001 mg ⁄L, 0.005 mg ⁄L or
0.010 mg ⁄L were added. After incubation for 20 h, 16 lL of the
dye indicator solution was added. Following an additional 4-h
incubation, 100 lL of the solubilisation stop solution was
added to each well. The results were quantified by ELISA as
the optical density at 570 nm of cultures exposed to gemifl-
oxacin or exposed to the diluent alone.
Statistics
All values were expressed as means ± two standard devia-
tions. Welch’s modified t-test was used in a computer software
package (InStat 2.0; GraphPad Software, San Diego, CA, USA)
to determine, for each donor, whether the differences in
cytokine secretion between LPS-stimulated monocytes treated
or not treated with gemifloxacin were statistically significant
(p 0.05).
Electrophoretic mobility shift assay and Northern blot
analysis
To determine whether inhibition of cytokine secretion was an
effect of gemifloxacin on gene transcription, the activation of
NF-jB and the steady state cytokine mRNA levels were
measured. LPS-induced production of several cytokines, inclu-
ding IL-1a and TNF-a, is dependent on NF-jB activation and
translocation into the nucleus [16,17]. Since gemifloxacin
inhibits secretion of multiple cytokines, the potential inhibition
of NF-jB activation by gemifloxacin was examined by gel
mobility shift assay. For these studies, the human monocytic
cell line THP-1 was selected, rather than isolated human
peripheral blood monocytes, to reduce the potential for
individual variation. In addition, initial studies revealed that
THP-1 cells secreted cytokines in response to LPS stimulation,
and that this secretion was inhibited by gemifloxacin in a
manner that was qualitatively similar to peripheral blood
monocytes. Thus, THP-1 cells were considered a suitable
model cell system to study the mechanism of action of
gemifloxacin.
THP-1 cells were seeded in 12-well plates at a density of
1 · 106 cells ⁄mL (1 mL ⁄well) and preincubated in the pres-
ence or absence of concentrations of gemifloxacin of
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0.001 mg ⁄L, 0.005 mg ⁄L or 0.01 mg ⁄L for 16–20 h. The cells
were then stimulated with 0.001 mg ⁄L of LPS for 20, 40, 60 or
80 min at 37 C. Nuclear extracts were prepared from THP-1
cells as described by Delude et al. [18] with slight modifica-
tions. Briefly, cells were collected by centrifugation at 500 g
for 4 min at 4 C and washed twice with cold PBS. There-
after, the cells were resuspended in 400 lL of buffer I (10 mM
Tris pH 7.8, 5 mM MgCl2, 10 mM KCl, 0.3 mM EGTA, 0.3 M
sucrose, 0.5 mM dithiothreitol, 1 mM PMSF and P8340
protease inhibitor cocktail (Sigma) 0.625% v/v), and incuba-
ted at 4 C for 15 min. A 25-lL aliquot of Nonidet P40 10%
v ⁄v was added and the solution vortexed for 10 s. The lysate
was centrifuged at 7200 g for 10 s at 4 C and the pellet
(nuclear fraction) resuspended in 75 lL of buffer II (20 mM
Tris pH 7.8, 5 mM MgCl2, 320 mM KCl, 0.2 mM EGTA, 0.5 mM
dithiothreitol, 1 mM PMSF, P8340 2.5% v ⁄v) and incubated at
4 C for 15 min. Samples were centrifuged at 20 000 g for
15 min at 4 C and the supernatants (nuclear extracts) stored
at ) 80 C until analysis. The protein content of the nuclear
extracts was measured with the BCA protein assay (Pierce,
Rockford, IL, USA). Samples (4 lg) of protein were incubated
with 1 ng P32-labelled double-stranded oligonucleotide
(5¢-CAGAGGGGACTTTCCGAGAG-3¢) in binding buffer (gly-
cerol 12% v ⁄v, 12 mM HEPES pH 7.9, 0.6 mM EDTA, 60 mM
KCl, 5 mM MgCl2, 0.6 mM dithiothreitol and poly dI-dC
200 lg ⁄mL) at room temperature for 35 min. Incubation with
albumin in amounts equivalent to the volume of the nuclear
extracts was included as a negative control. The reaction
mixtures were separated by non-denaturing polyacrylamide
gel (5% w ⁄v) electrophoresis in 0.5 · TBE buffer (45 mM Tris-
borate, 1 mM EDTA, pH 8.0) and the amount of DNA binding
measured by autoradiography. Specificity of binding was
assessed with a 25-fold molar excess of unlabelled double-
stranded oligonucleotide.
Northern blotting was performed to determine the effect of
gemifloxacin on the steady state levels of IL-1b and TNF-a
mRNA in the LPS-treated THP-1 cells. These cells were
cultured either alone or in the presence of gemifloxacin
0.005 mg ⁄L or 0.010 mg ⁄L in quadruplicate wells of microtitre
plates. After culture for 0, 2, 4, 8 and 24 h, the plates were
centrifuged and supernatants collected to determine secretion
of IL-1b and TNF-a by ELISA as described above. The pelleted
cells were collected and total RNA was extracted with a
Stat)60 kit (Tel.Test, Friendswood, TX, USA) according to the
manufacturer’s instruction. Thereafter, total RNA
(0.015 mg ⁄L) of each monocyte sample was electrophoresed
under denaturing conditions in agarose 1.2% w ⁄v gels with
2.2 M formaldehyde, transferred to Nytran membranes (Sch-
leicher and Schuell, Keene, NH, USA) and cross-linked by UV
irradiation. cDNA probes of human IL-1b (30-mer, GenBank
Accession Number: M10988), TNF-a (27-mer, GenBank Acces-
sion Number: K02770) and b-actin (29-mer GenBank Accession
Number: X00351) (R & D Systems, Minneapolis, MN, USA),
radiolabelled with c-32P ATP (Promega), were used in the
hybridisation procedure. The membranes hybridised
with human IL-1b and TNF-a probes were exposed in a
phosphor-imager cassette (Molecular Dynamics, Sunnyvale,
CA, USA) for 18 h, while the membranes hybridised with
human b-actin probe were exposed in a phosphor-imager
cassette for 8 h. Hybridisation was visualised by phosphor-
imager (Storm 860; Molecular Dynamics) and the signals
normalised to human b-actin by image densitometry. Signal
data were expressed as absorbency units.
R E S U L T S
Effect of gemifloxacin on cytokine secretion
Treatment of monocytes with LPS resulted in a
significant (p < 0.001) increase in accumulation of
each of the cytokines in the supernatants of the
cultured monocytes. For IL-1a, IL-1b, IL-6 and IL-
10, the increase was noted after incubation for 6 h
and 24 h, and for TNF-a after incubation for 3 h,
6 h and 24 h (Fig. 1). Treatment of the monocytes
with LPS plus gemifloxacin resulted in inhibition
of secretion of each cytokine by monocytes from
each of the eight donors. Fig. 1 shows represen-
tative results for IL-1a, IL-1b, IL-6, IL-10 and
TNF-a. Statistically significant inhibition (p < 0.01)
of secretion of IL-1a, IL-1b, IL-6 and IL-10
occurred after 6 and 24 h, and was most pro-
nounced after incubation of the monocytes with
LPS and gemifloxacin for 24 h. Significant inhibi-
tion (p < 0.01) of secretion of TNF-a occurred at
each time period examined. A dose–response
was observed.
Effect of gemifloxacin on NF-jB activation
Cells incubated with gemifloxacin alone, or in the
absence of LPS, did not induce NF-jB activation
(Fig. 2). In contrast, addition of LPS alone induced
NF-jB activation in a time-dependent manner,
with a maximal response observed at or near
60 min after addition of LPS. The specificity of the
activation was established with an excess of
unlabelled competitor. Pre-incubation with gemi-
floxacin 0.001 mg ⁄L, 0.005 mg ⁄L or 0.010 mg ⁄L
not only failed to reduce activation of NF-jB in
LPS-stimulated cells, but also caused a slight
increase in the levels of activation of the
NF-jB transcription factor. This was observed
in four separate experiments. The absence of
inhibition was observed at all intervals measured
from 20 min to 6 h. These results revealed that
gemifloxacin did not interfere with the LPS-
induced activation of NF-jB, and suggested an
alternative mechanism of action to explain the
inhibitory effect of gemifloxacin on secretion of
cytokines.
ELISA to determine the effect of gemifloxacin
on secretion of IL-1b and TNF-a by LPS-stimula-
ted THP-1 cells revealed that both cytokines were
secreted following LPS stimulation. Treatment
with gemifloxacin inhibited secretion of TNF-a
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Fig. 1. Effect of different concentrations of gemifloxacin (Gemi) on secretion of IL-1a, IL-1b, IL-6, IL-10 and TNF-a by
human monocytes (M) stimulated with lipopolysaccharide (LPS). + ¼ p < 0.001 calculated for M only and M + LPS, while
* ¼ p < 0.01 calculated for M + LPS and M + LPS + concentration of Gemi.
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Fig. 2. Results of the electrophoretic
shift-mobility assay. Lane 13 shows
that cells incubated with gemifloxa-
cin alone did not induce NF-jB
activation. The locations of the
unbound labelled oligonucleotide
probe and the NF-jB-DNA complex
are shown. Gemifloxacin concentra-
tions of 0.001, 0.005 and 0.010 mg ⁄L
gave identical results. The results
are representative of four separate
experiments.
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significantly (p < 0.01) at 2 h, 4 h and 8 h,
whereas secretion of IL-1b was inhibited signifi-
cantly at 4 h, 8 h and 24 h (Fig. 3).
Northern blotting revealed that treatment of
the THP-1 cells with gemifloxacin 0.005 mg ⁄L
resulted in a non-significant increase in the levels
of TNF-a at each time period. However, treat-
ment with 0.01 mg ⁄L did not result in any
increase above the levels noted in the prepar-
ation from the control cells (Fig. 4). IL-1b mRNA
levels were also increased by treatment of THP-1
cells with gemifloxacin 0.005 or 0.01 mg ⁄L, but
the increase was observed only after 2 h (data
not shown).
D I S C U S S I O N
The results of this study indicated that gemifl-
oxacin strongly inhibits secretion of IL-1a, IL-1b,
IL-6, IL-10 and TNF-a by healthy monocytes
stimulated with LPS at concentrations that are
higher than those achieved in healthy volunteers
treated with single doses of 20–800 mg [19].
Whereas each of the cytokines examined was
inhibited, the most pronounced effects were
noted with IL-1a, IL-1b and TNF-a and occurred
after incubation for 6 h and 24 h. This is of
interest since, in treated volunteers, the mean
terminal phase elimination half-life was
7.4 ± 2.0 h [19]. Thus, the inhibitory effect of
gemifloxacin on cytokine secretion occurred when
high concentrations of the drug were used for a
prolonged period. However, the down-regulatory
effect of gemifloxacin is of interest, particularly
for IL-1a since this cytokine is a major pro-
inflammatory cytokine and mediates many com-
ponents of the acute-phase response to infectious
and non-infectious agents [20,21]. The biological
activities of IL-1b are indistinguishable from those
of IL-1a [22]. Thus, inhibition of secretion of IL-1b
was not surprising. TNF-a shares many biological
properties with IL-1a, although the cell receptors
for these two cytokines are distinct [3]. In the
present study, inhibition of secretion of TNF-a
occurred following incubation of the LPS-stimu-
lated monocytes with gemifloxacin 0.001 mg ⁄L
for as little as 3 h. For the other cytokines
examined, the greatest in-vitro inhibitory effect
occurred with concentrations of 0.005 mg ⁄L and
0.01 mg ⁄L. As mentioned above, these in-vitro
concentrations are high and may not be attainable
in humans treated with conventional dosing.
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Fig. 4. Northern blot analysis of the effect of different
concentrations of gemifloxacin (Gemi) on the expression of
TNF-a mRNA in LPS-stimulated THP-1 cells. Controls
were THP-1 cells stimulated with LPS only. The mRNA
readings were normalised to human b-actin and the
signals are expressed as absorbency units.
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However, this may not rule out an in-vivo effect
of gemifloxacin on cytokine modulation by mono-
cytes.
The inhibitory effect of gemifloxacin appears to
be similar to that observed with trovafloxacin.
This antibiotic, in concentrations achievable in
humans, suppressed secretion of each of the
cytokines examined in the present study [6],
whereas moxifloxacin, an antibiotic structurally
related to trovafloxacin, inhibited secretion of
IL-1a by LPS-stimulated monocytes from each of
ten healthy donors, and secretion of TNF-a in six
of ten healthy donors [7]. Secretion of IL-6, IL-10
and IL-12 (p70) were not inhibited significantly by
moxifloxacin [7]. These results suggest differences
in immunomodulatory activity among antibiotics
of the same class.
Studies to determine the mechanisms involved
in in-vitro inhibition of secretion of cytokines by
antibiotics have focused mostly on macrolide
antibiotics [5,9,23]. Erythromycin at a concentra-
tion of 10)5 M inhibited IL-8-driven NF-jB tran-
scription in vitro by 37% [24]. Moreover,
erythromycin inhibited activation of NF-jB and
AP-1 transcription factors, which are both crucial
regulators of IL-8 expression, in both bronchial
epithelial cells [25] and THP-1 cells [26]. NF-jB
was also shown to be required for optimal CD40-
induced production of IL-12 [27]. These observa-
tions indicated that the transcription factors
NF-jB and AP-1 are at the centre of the mechan-
ism of action of macrolides on the inflammatory
process [5]. Thus, it is of interest that the results of
the present study revealed that, although treat-
ment with LPS induced activation of NF-jB in a
time-dependent manner, treatment with gemifl-
oxacin did not inhibit this activation at any of the
time intervals used in the experiment. In fact,
treatment with gemifloxacin induced a slight
increase in the level of activation of the NF-jB
factor. The reason for this observation is unclear.
Consistent with a post-transcriptional mechan-
ism of regulation was the observation that mRNA
levels for TNF-a and IL-1b were not decreased by
treatment of the THP-1 cells with gemifloxacin. As
was observed in the experiment to examine
activation of NF-jB, treatment with gemifloxacin
resulted in an increase in the levels of mRNA for
TNF-a and IL-1b, although, as the ELISA results
indicated, secretion of these cytokines was inhib-
ited by treatment of the THP-1 cells with gemifl-
oxacin. These results suggest that gemifloxacin
inhibits cytokine secretion by an entirely different
mechanism than that reported for erythromycin
and clarithromycin, which suppressed mRNA
levels as well as secretion of IL-6 from bronchial
epithelial cells [28]. Gemifloxacin could interfere
with cytokine synthesis at the level of protein
translation or the secretion of cytokine into the
medium. Each mechanism could account for the
inhibition of cytokine secretion.
In summary, the results of this study indicate
that gemifloxacin is an inhibitor of secretion of
cytokines by human monocytes stimulated with
LPS. The inhibitory effect does not appear to be
related to suppression of the transcription factor
NF-jB or regulation of levels of cytokine mRNA.
Although the inhibition of cytokine secretion by
gemifloxacin occurred when high concentrations
of the drug were used for a prolonged period, it
may have an important effect on the modulation
of the immune system, since the drug concentra-
tion at tissue and intracellular levels may be
considerably higher than in serum.
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